

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/655,861
				Filing Date	September 5, 2003
				First Named Inventor	Yi Wang
				Art Unit	1644
				Examiner Name	P. Gambel
Sheet	2	of	2	Attorney Docket Number	ALXN-P01-102

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kaplan, Mariana, "Eculizumab," Current Opinion in Investigational Drugs, Vol. 3(7); pp. 1017-1023 (2002).	
		Moongkarndi et al., "Immunological and functional properties of two monoclonal antibodies against human C5," Immunobiol. Vol. 165, page 323 (1983).	
		Moongkarndi et al., "Monoclonal antibodies against the fifth component of human complement," Immunobiol, Vol 162; page 397 (1982).	
		Neurogen Reports Phase IIa Clinical Trial Results for Oral Asthma Drug, Press Release dated January 13, 2004.	

Examiner Signature	/Phillip Gambel/	Date Considered	10/05/2011
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.